Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05667116 · ClinicalTrials.gov registry record
eVusheld Assessment reaL wORld Effectiveness at UPMC
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 4,232
- Enrollment target
NCT05667116 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 4,232 participants.
The verdict
NCT05667116 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 4,232 participants
- Enrollment target
Study Summary
An AstraZeneca-sponsored observational, electronic healthcare record (EHR)-embedded retrospective cohort study to assess the real-world effectiveness of EVUSHELD against SARS-CoV-2 infection, COVID-19-related hospitalization, and other COVID-19 related outcomes in the total EUA-eligible patient population in the University of Pittsburgh Medical Center (UPMC) Health System.
Interventions
- DRUG EVUSHELD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,232 participants |
| Start Date | 2023-01-09 |
| Est. Completion | 2023-07-24 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05667116
The ClinicalTrials.gov registry entry for NCT05667116 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 4,232 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EVUSHELD is the first listed.
NCT05667116 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05667116 about?
NCT05667116 is a clinical study titled "eVusheld Assessment reaL wORld Effectiveness at UPMC". An AstraZeneca-sponsored observational, electronic healthcare record (EHR)-embedded retrospective cohort study to assess the real-world effectiveness of EVUSHELD against SARS-CoV-2 infection, COVID-19-related hospitalization, and other COVID-19 related outcomes in the total EUA-eligible patient popu...
What is the current status of trial NCT05667116?
This trial is currently completed. The enrollment target is 4,232 participants. The study started on 2023-01-09. Estimated completion is 2023-07-24.
What interventions are being tested in trial NCT05667116?
The interventions under investigation include: EVUSHELD (DRUG).
Who is sponsoring clinical trial NCT05667116?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.